Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma
Alberto Papi, Irene Braithwaite, Stefan Ebmeier, Robert J. Hancox, Tim Harrison, Mark Holliday, Claire Houghton, Luca Morandi, Karen Oldfield, Ian D. Pavord, Helen K. Reddel, Mathew Williams, Mark Weatherall, Richard Beasley
Source: Eur Respir J, 57 (2) 2003064; 10.1183/13993003.03064-2020
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Alberto Papi, Irene Braithwaite, Stefan Ebmeier, Robert J. Hancox, Tim Harrison, Mark Holliday, Claire Houghton, Luca Morandi, Karen Oldfield, Ian D. Pavord, Helen K. Reddel, Mathew Williams, Mark Weatherall, Richard Beasley. Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma. Eur Respir J, 57 (2) 2003064; 10.1183/13993003.03064-2020
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Formoterol Turbuhaler as reliever medication in patients with acute asthma Source: Eur Respir J 2006; 27: 735-741 Year: 2006
Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
As-needed formoterol has an improved safety profile compared with as-needed terbutaline in mild intermittent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
Low dose inhaled budesonide with and without formoterol in steroid free patients with mild persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001
Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
Effect of budesonide/formoterol, budesonide and terbutaline on exercise-induced bronchoconstriction in mild intermittent asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011
Intermittent therapy with budesonide/formoterol in children with moderate asthma. Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017
Triple combination of montelukast or tiotropium and inhaled corticosteroids plus long-acting ß2-agonist in persistent asthma Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018
Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy Source: Annual Congress 2010 - Management of airway disease Year: 2010
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007
Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Early and sustained benefits of budesonide and formoterol in a single inhaler vs fluticasone in moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001
Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid Source: Eur Respir J 2002; 20: Suppl. 38, 113s Year: 2002